Current Diabetes Reports

, Volume 4, Issue 1, pp 53–62 | Cite as

The metabolic syndrome in children and adolescents

  • Martha L. Cruz
  • Michael I. Goran


The metabolic syndrome was recently defined by the Adult Treatment Panel III. Despite a lack of uniform definition of the syndrome in pediatrics, recent studies have shown that the syndrome develops during childhood and is highly prevalent among overweight children and adolescents. The hypothesized central role of insulin resistance and obesity as a common underlying feature of the metabolic syndrome also appears to be already manifested in childhood. In view of the current obesity epidemic in children and adolescents, there is a vital need to provide adequate guidelines for the definition of the metabolic syndrome in pediatrics and for the development of screening and treatment strategies. This article focuses on the above issues, as well as on the impact of the syndrome on two major disease outcomes, type 2 diabetes and cardiovascular disease.


Insulin Resistance Metabolic Syndrome Impaired Glucose Tolerance Impaired Fasting Glucose National Cholesterol Education Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM:NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.PubMedCrossRefGoogle Scholar
  2. 2.
    Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.PubMedCrossRefGoogle Scholar
  3. 3.
    Meigs JB, Wilson PW, Nathan DM, et al.: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003, 52:2160–2167.PubMedCrossRefGoogle Scholar
  4. 4.
    Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.PubMedCrossRefGoogle Scholar
  5. 5.
    Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.PubMedCrossRefGoogle Scholar
  6. 6.
    Laaksonen DE, Lakka HM, Niskanen LK, et al. : Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070–1077.PubMedCrossRefGoogle Scholar
  7. 7.
    Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002, 51:3120–3127.PubMedCrossRefGoogle Scholar
  8. 8.
    Cook S, Weitzman M, Auinger P, et al.: Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003, 157:821–827. Provides prevalence rates of the metabolic syndrome in US adolescents who participated in the NHANES III.PubMedCrossRefGoogle Scholar
  9. 9.
    Chen W, Srinivasan SR, Elkasabany A, Berenson GS: Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black-White) population of children, adolescents, and young adults: the Bogalusa Heart Study. Am J Epidemiol 1999, 150:667–674.PubMedGoogle Scholar
  10. 10.
    Chen W, Bao W, Begum S, et al.: Age-related patterns of the clustering of cardiovascular risk variables of syndrome X from childhood to young adulthood in a population made up of black and white subjects: the Bogalusa Heart Study. Diabetes 2000, 49:1042–1048.PubMedCrossRefGoogle Scholar
  11. 11.
    Raitakari OT, Porkka KV, Ronnemaa T, et al.: The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study. Diabetologia 1995, 38:1042–1050.PubMedGoogle Scholar
  12. 12.
    Cruz ML, Weigensberg MJ, Huang TTK, et al.: The metabolic syndrome in overweight hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004, in press. Results of this study show that decreased insulin sensitivity is related to the metabolic syndrome and this relationship is independent of body fatness.Google Scholar
  13. 13.
    Ogden CL, Flegal KM, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 2002, 288:1728–1732.PubMedCrossRefGoogle Scholar
  14. 14.
    Strauss RS, Pollack HA: Epidemic increase in childhood overweight, 1986–1998. JAMA 2001, 286:2845–2848.PubMedCrossRefGoogle Scholar
  15. 15.
    Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents [no authors listed]. Pediatrics 1996, 98:649–658.Google Scholar
  16. 16.
    Hickman TB, Briefel RR, Carroll MD, et al.: Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med 1998, 27:879–890.PubMedCrossRefGoogle Scholar
  17. 17.
    McKeigue PM, Ferrie JE, Pierpoint T, Marmot MG: Association of early-onset coronary heart disease in South Asian men with glucose intolerance and hyperinsulinemia. Circulation 1993, 87:152–161.PubMedGoogle Scholar
  18. 18.
    National Institutes of Health: The Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 01-3670. Bethesda, MD: National Institutes of Health; NIH Publication 01-3670; 2001.Google Scholar
  19. 19.
    1Reaven GM: Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991, 121:1283–1288.CrossRefGoogle Scholar
  20. 20.
    1Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.CrossRefGoogle Scholar
  21. 21.
    Liese AD, Mayer-Davis EJ, Tyroler HA, et al.: Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann Epidemiol 1997, 7:407–416.PubMedCrossRefGoogle Scholar
  22. 22.
    Ferrannini E, Muscelli E, Stern MP, Haffner SM: Differential impact of insulin and obesity on cardiovascular risk factors in non-diabetic subjects. Int J Obes Relat Metab Disord 1996, 20:7–14.PubMedGoogle Scholar
  23. 23.
    Sinaiko AR, Jacobs DR Jr, Steinberger J, et al.: Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr 2001, 139:700–707.PubMedCrossRefGoogle Scholar
  24. 24.
    Srinivasan SR, Myers L, Berenson GS: Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study. Diabetes 2002, 51:204–209.PubMedCrossRefGoogle Scholar
  25. 25.
    Cruz ML, Huang TTK, Johnson MS, et al.: Insulin sensitivity and blood pressure in black and white children. Hypertension 2002, 40:18–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Cruz ML, Bergman RN, Goran MI: Unique effect of visceral fat on insulin sensitivity in obese Hispanic children with a family history of type 2 diabetes. Diabetes Care 2002, 25:1631–1636.PubMedCrossRefGoogle Scholar
  27. 27.
    Weiss R, Dufour S, Taksali SE, et al.: Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003, 362:951–957.PubMedCrossRefGoogle Scholar
  28. 28.
    Berenson GS, Srinivasan SR, Bao W, et al.: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998, 338:1650–1656.PubMedCrossRefGoogle Scholar
  29. 29.
    McGill HC Jr, McMahan CA, Herderick EE, et al.: Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002, 105:2712–2718.PubMedCrossRefGoogle Scholar
  30. 30.
    Sinha R, Fisch G, Teague B, et al.: Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002, 346:802–810.PubMedCrossRefGoogle Scholar
  31. 31.
    Type 2 diabetes in children and adolescents. American Diabetes Association [no authors listed]. Pediatrics 2000, 105:671–680.Google Scholar
  32. 32.
    Goran MI, Bergman RN, Avila Q, et al.: Impaired glucose tolerance and reduced beta-cell function in overweight Hispanic children. J Clin Endocrinol Metab 2004, in press. Study shows early evidence of impaired β-cell function in overweight Hispanic adolescents with impaired glucose tolerance.Google Scholar
  33. 33.
    Saydah SH, Miret M, Sung J, et al.: Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001, 24:1397–1402.PubMedCrossRefGoogle Scholar
  34. 34.
    Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 2001, 24:447–453.PubMedCrossRefGoogle Scholar
  35. 35.
    Dinneen SF, Maldonado DIII, Leibson CL, et al.: Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 1998, 21:1408–1413.PubMedCrossRefGoogle Scholar
  36. 36.
    Lillioja S, Mott DM, Spraul M, et al.: Insulin resistance and insulin secretory dysfunction as precursors of noninsulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993, 329:1988–1992.PubMedCrossRefGoogle Scholar
  37. 37.
    Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796–2803.PubMedCrossRefGoogle Scholar
  38. 38.
    Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787–794.PubMedCrossRefGoogle Scholar
  39. 39.
    Fagot-Campagna A, Saaddine JB, Flegal KM, Beckles GL:Diabetes, impaired fasting glucose, and elevated HbA1c in U.S. adolescents: the Third National Health and Nutrition Examination Survey. Diabetes Care 2001, 24:834–837.PubMedCrossRefGoogle Scholar
  40. 40.
    Bao W, Srinivasan SR, Valdez R, et al.: Longitudinal changes in cardiovascular risk from childhood to young adulthood in offspring of parents with coronary artery disease: the Bogalusa Heart Study. JAMA 1997, 278:1749–1754.PubMedCrossRefGoogle Scholar
  41. 41.
    Steinberger J, Moran A, Hong CP, et al.: Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J Pediatr 2001, 138:469–473.PubMedCrossRefGoogle Scholar
  42. 42.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care 2003, 26:3160–3167.CrossRefGoogle Scholar
  43. 43.
    National Cholesterol Education Panel: Report of the expert panel on blood cholesterol levels in children and adolescents. NIH Publication No 91-2732. Bethesda, MD: National Heart, Lung and Blood Institute and National Institutes of Health; 1991:119.Google Scholar
  44. 44.
    Barlow SE, Dietz WH: Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998, 102:E29.PubMedCrossRefGoogle Scholar
  45. 45.
    Williams CL, Hayman LL, Daniels SR, et al.: Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002, 106:143–160.PubMedCrossRefGoogle Scholar
  46. 46.
    Kavey RE, Daniels SR, Lauer RM, et al.: American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003, 107:1562–1566.PubMedCrossRefGoogle Scholar
  47. 47.
    American Diabetes Association: clinical practice recommendations 2002 [no authors listed]. Diabetes Care 2002, 25(suppl 1):S1–S147.Google Scholar
  48. 48.
    Steinberger J, Daniels SR: Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003, 107:1448–1453.PubMedCrossRefGoogle Scholar
  49. 49.
    Kang HS, Gutin B, Barbeau P, et al.: Physical training improves insulin resistance syndrome markers in obese adolescents. Med Sci Sports Exerc 2002, 34:1920–1927.PubMedCrossRefGoogle Scholar
  50. 50.
    Bernhardt DT, Gomez J, Johnson MD, et al.: Strength training by children and adolescents. Pediatrics 2001, 107:1470–1472.PubMedCrossRefGoogle Scholar
  51. 51.
    Pereira MA, Ludwig DS: Dietary fiber and body-weight regulation. Observations and mechanisms. Pediatr Clin North Am 2001, 48:969–980.PubMedCrossRefGoogle Scholar
  52. 52.
    Bhathena SJ, Velasquez MT: Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 2002, 76:1191–1201.PubMedGoogle Scholar
  53. 53.
    Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001, 107:E55.PubMedCrossRefGoogle Scholar
  54. 54.
    Antonucci T, Whitcomb R, McLain R, et al.: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1987, 20:188–193.CrossRefGoogle Scholar
  55. 55.
    Ghazzi MN, Perez JE, Antonucci TK, et al.: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997, 46:433–439.PubMedCrossRefGoogle Scholar
  56. 56.
    Miyazaki Y, Mahankali A, Matsuda M, et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784–2791.PubMedCrossRefGoogle Scholar
  57. 57.
    Yamasaki Y, Kawamori R, Wasada T, et al.: Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med 1997, 183:173–183.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Martha L. Cruz
    • 1
  • Michael I. Goran
    • 1
  1. 1.Department of Preventive Medicine, Physiology and Biophysics, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations